
JNJ
Johnson & Johnson
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
174.540
Open
173.000
VWAP
174.12
Vol
5.88M
Mkt Cap
420.06B
Low
172.695
Amount
1.02B
EV/EBITDA(TTM)
14.48
Total Shares
2.41B
EV
447.99B
EV/OCF(TTM)
19.45
P/S(TTM)
4.62
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
22.94B
+4.8%
2.690
-2.87%
24.05B
+6.78%
2.566
+25.79%
23.73B
+5.58%
2.750
+13.62%
Estimates Revision
The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 2.37% over the past three months. During the same period, the stock price has changed by 17.50%.
Revenue Estimates for FY2025
Revise Upward

+2.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+2.33%
In Past 3 Month
Stock Price
Go Up

+17.50%
In Past 3 Month
19 Analyst Rating

1.38% Upside
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 176.82 USD with a low forecast of 160.00 USD and a high forecast of 192.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
10 Hold
0 Sell
Moderate Buy

1.38% Upside
Current: 174.420

Low
160.00
Averages
176.82
High
192.00

1.38% Upside
Current: 174.420

Low
160.00
Averages
176.82
High
192.00
Erste Group
Hans Engel
Hold
to
Buy
upgrade
2025-07-23
Reason
Erste Group
Hans Engel
Price Target
2025-07-23
upgrade
Hold
to
Buy
Reason
Erste Group analyst Hans Engel upgraded Johnson & Johnson to Buy from Hold. The firm, which notes that J&J has a higher operating margin and return on equity than its competitors, expects the stock price to rise further in the medium term given the company's improved growth prospects.
Barclays
Matt Miksic
Equal Weight
maintain
$165 -> $176
2025-07-17
Reason
Barclays
Matt Miksic
Price Target
$165 -> $176
2025-07-17
maintain
Equal Weight
Reason
Barclays analyst Matt Miksic raised the firm's price target on Johnson & Johnson to $176 from $165 and keeps an Equal Weight rating on the shares following the Q2 report. The firm says the company's sales and earnings beat on execution and currency.
Bernstein
Market Perform
maintain
$159 -> $172
2025-07-17
Reason
Bernstein
Price Target
$159 -> $172
2025-07-17
maintain
Market Perform
Reason
Bernstein raised the firm's price target on Johnson & Johnson to $172 from $159 and keeps a Market Perform rating on the shares following a solid beat and raise. The firm notes the company expects second half of 2025 acceleration despite Stelara LOE.
BofA
Neutral
maintain
$161 -> $175
2025-07-17
Reason
BofA
Price Target
$161 -> $175
2025-07-17
maintain
Neutral
Reason
BofA raised the firm's price target on Johnson & Johnson to $175 from $161 and keeps a Neutral rating on the shares. The firm's target is still based on a sum-of-the-parts valuation, but now using its new 2026 EPS estimates, the analyst tells investors after J&J reported a Q2 EPS beat and raised 2025 guidance.
Guggenheim
Neutral
maintain
$164 -> $167
2025-07-17
Reason
Guggenheim
Price Target
$164 -> $167
2025-07-17
maintain
Neutral
Reason
Guggenheim raised the firm's price target on Johnson & Johnson to $167 from $164 and keeps a Neutral rating on the shares after the company delivered a "strong" Q2 and gave an "encouraging outlook" for the company's growth prospects in the second half. The firm keeps a Neutral rating on J&J shares as it waits for more visibility on the emerging Innovative Medicine pipeline that will need to offset Stelara's decline, the analyst noted.
UBS
Buy
maintain
$180 -> $190
2025-07-17
Reason
UBS
Price Target
$180 -> $190
2025-07-17
maintain
Buy
Reason
UBS raised the firm's price target on Johnson & Johnson to $190 from $180 and keeps a Buy rating on the shares. Johnson & Johnson is well-positioned to deliver upside into the second half following the strong beat and raise quarter, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 15.94, compared to its 5-year average forward P/E of 16.18. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
16.18
Current PE
15.94
Overvalued PE
17.39
Undervalued PE
14.96
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
12.94
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.73
Undervalued EV/EBITDA
12.15
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
4.48
Current PS
0.00
Overvalued PS
4.81
Undervalued PS
4.15
Financials
Annual
Quarterly
FY2025Q2
YoY :
+5.77%
23.74B
Total Revenue
FY2025Q2
YoY :
-1.24%
7.02B
Operating Profit
FY2025Q2
YoY :
+18.16%
5.54B
Net Income after Tax
FY2025Q2
YoY :
+18.65%
2.29
EPS - Diluted
FY2025Q2
YoY :
-39.12%
2.84B
Free Cash Flow
FY2025Q2
YoY :
-2.12%
67.94
Gross Profit Margin - %
FY2025Q2
YoY :
-12.71%
20.47
FCF Margin - %
FY2025Q2
YoY :
+11.69%
23.32
Net Margin - %
FY2025Q2
YoY :
-41.33%
19.29
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.1M
USD
1
3-6
Months
0.0
USD
0
6-9
Months
3.2M
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
147.2K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
679.6K
Volume
29
6-9
Months
557.5K
Volume
41
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
15
957.0K
Volume
Months
6-9
27
2.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress areBuying! The buying amount has increased103.13%over the last month.
Sold
0-3
Months
73.0K
USD
3
3-6
Months
338.0K
USD
13
6-9
Months
366.0K
USD
4
0-12
Months
40.5K
USD
2
Bought
0-3
3
48.5K
USD
Months
3-6
12
243.0K
USD
Months
6-9
14
161.0K
USD
Months
0-12
6
48.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.1M
USD
1
3-6
Months
0.0
USD
0
6-9
Months
3.2M
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
147.2K
USD
Months
0-12
0
0.0
USD
Months
JNJ News & Events
Events Timeline
2025-08-13 (ET)
2025-08-13
15:54:48
Pharma tariff announcement likely 'weeks away,' Reuters reports


2025-08-08 (ET)
2025-08-08
09:29:30
Trump, pharma industry discuss increasing medicine spending abroad, Reuters says


2025-08-05 (ET)
2025-08-05
08:22:27
Trump says separate tariff announcements coming for semi chips, pharmaceuticals

Sign Up For More Events
Sign Up For More Events
News
9.0
08-13BenzingaVor Bio Rallies On Strong Data For Autoimmune Drug Candidate
6.5
08-13NASDAQ.COMIf You're In Your 20's, Consider Buying These 3 Healthcare Stocks
3.0
08-11Yahoo FinanceNon-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations
Sign Up For More News
People Also Watch

ADBE
Adobe Inc
351.070
USD
+3.73%

UNH
UnitedHealth Group Inc
271.810
USD
+3.91%

MCD
McDonald's Corp
305.070
USD
+1.14%

CRM
Salesforce Inc
237.030
USD
+2.32%

COST
Costco Wholesale Corp
978.850
USD
-1.25%

PFE
Pfizer Inc
25.160
USD
+2.07%

TMO
Thermo Fisher Scientific Inc
484.790
USD
+1.55%

KO
Coca-Cola Co
70.460
USD
-0.35%

PEP
PepsiCo Inc
149.350
USD
+1.69%

PG
Procter & Gamble Co
155.410
USD
+0.21%
FAQ

What is Johnson & Johnson (JNJ) stock price today?
The current price of JNJ is 174.42 USD — it has increased 0.95 % in the last trading day.

What is Johnson & Johnson (JNJ)'s business?

What is the price predicton of JNJ Stock?

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Johnson & Johnson (JNJ)'s fundamentals?

How many employees does Johnson & Johnson (JNJ). have?
